CMV reactivation in ICU patients

Not Applicable

• Conditions: Health Condition 1: B108- Other human herpesvirus infection

• Registration Number: CTRI/2021/01/030371
• Lead Sponsor: Sanjay Gandhi Post Graduate Institute of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

All adult ICU patients (age >= 18 years) who had septic shock will be considering for inclusion in this study.

Exclusion Criteria

1.Consent not given.

2.Expected survival < 72 hours.

3.Use of antiviral agent cidofovir, foscarnet, ganciclovir, valgancyclovir [HSV treatment doses of acyclovir, valacyclovir, or famciclovir permitted]) within the last 7 days.

4.Known or suspected underlying immune deficiency [history of solid organ or stem cell transplantation, infection with the human immunodeficiency virus, hematological malignancy, use of immunosuppressive medication (more than 0.1 mg prednisone per kilo for more than 3 months, more than 75 mg prednisone per day for more than 1 week, or equivalent), chemotherapy/radiotherapy in the year before ICU admission, and any known humoral or cellular immune deficiency].

5.Pregnancy.

Study & Design

• Study Type: Observational
• Study Design: Not specified